Skip to main content
SpringerLink
Log in

Zervixkarzinomrezidiv: PD-1-Hemmer in der Zweitlinie

Gesamtüberleben von Patientinnen mit rezidvierendem Zervixkarzinom verbessert

  • Journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Tewari KS et al. N Engl J Med. 2022;386(6):544-55

  2. Colombo N et al. N Engl J Med. 2021;385(20):1856-67

Download references

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe, Helios Dr. Horst Schmidt Kliniken Wiesbaden, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Deutschland

    Michael Eichbaum

  2. Universitäts-Frauenklinik Frankfurt am Main, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland

    Christine Eichbaum

Authors
  1. Michael Eichbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Eichbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Eichbaum.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eichbaum, M., Eichbaum, C. Gesamtüberleben von Patientinnen mit rezidvierendem Zervixkarzinom verbessert. InFo Hämatol Onkol 25, 35–37 (2022). https://doi.org/10.1007/s15004-022-9105-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-022-9105-4

Search

Navigation